Kathleen Dorris
A5039734669- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Brain Metastases and Treatment
- Childhood Cancer Survivors' Quality of Life
- Pituitary Gland Disorders and Treatments
- Radiopharmaceutical Chemistry and Applications
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Research Studies
- Meningioma and schwannoma management
- Neurofibromatosis and Schwannoma Cases
- Chromatin Remodeling and Cancer
- Cancer Immunotherapy and Biomarkers
- Ocular Oncology and Treatments
- Protein Degradation and Inhibitors
- Advanced Breast Cancer Therapies
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Nanoplatforms for cancer theranostics
- Radiation Therapy and Dosimetry
- Radiomics and Machine Learning in Medical Imaging
- ATP Synthase and ATPases Research
- Ferroptosis and cancer prognosis
- PARP inhibition in cancer therapy
- Medical Imaging Techniques and Applications
Children's Hospital Colorado
2016-2025
University of Colorado Denver
2016-2025
University of Colorado Cancer Center
2022-2025
Morgan Adams Foundation
2017-2024
Center for Cancer and Blood Disorders
2016-2024
University of Colorado Anschutz Medical Campus
2016-2024
Boston Children's Hospital
2015
Cincinnati Children's Hospital Medical Center
2014
University Hospital Heidelberg
2013
Heidelberg University
2013
Abstract Background Diagnosis of diffuse intrinsic pontine glioma (DIPG) has relied on imaging studies, since the appearance is pathognomonic, and surgical risk was felt to be high unlikely affect therapy. The DIPG Biology Treatment Study (DIPG-BATS) reported here incorporated a biopsy at presentation stratified subjects receive FDA-approved agents chosen basis specific biologic targets. Methods Subjects were eligible for trial if clinical features newly diagnosed tumor consistent with DIPG....
Abstract Background Recurrent brain tumors are the leading cause of cancer death in children. Indoleamine 2,3-dioxygenase (IDO) is a targetable metabolic checkpoint that, preclinical models, inhibits anti-tumor immunity following chemotherapy. Methods We conducted phase I trial (NCT02502708) oral IDO-pathway inhibitor indoximod children with recurrent or newly diagnosed diffuse intrinsic pontine glioma (DIPG). Separate dose-finding arms were performed for combination temozolomide (200...
Abstract Background The use of next‐generation sequencing for fusion identification is being increasingly applied and aids our understanding tumor biology. Some fusions are responsive to approved targeted agents, while others have future potential therapeutic targeting. Although some pediatric central nervous system tumors may be cured with surgery alone, many require adjuvant therapy associated acute long‐term toxicities. Identification targetable can shift the treatment paradigm toward...
Radiation-induced high-grade gliomas (RIGs) are an incurable late complication of cranial radiation therapy. We performed DNA methylation profiling, RNA-seq, and sequencing on 32 RIG tumors in vitro drug screen two cell lines. report that based methylation, RIGs cluster primarily with the pediatric receptor tyrosine kinase I glioma subtype. Common copy-number alterations include Chromosome (Ch.) 1p loss/1q gain, Ch. 13q 14q loss; focal PDGFRA CDK4 gain CDKN2A BCOR loss. Transcriptomically,...
Central nervous system (CNS) cancers account for approximately one quarter of all pediatric tumors and are the leading cause cancer-related death in children. More than 4,000 brain CNS diagnosed each year children teens, incidence rate has remained stagnant recent years. The most common malignant gliomas, embryonal consisting predominately medulloblastomas, germ cell tumors. inaugural version NCCN Guidelines Pediatric Nervous System Cancers focuses on diagnosis management patients with...
Diffuse midline gliomas (DMG) are highly invasive brain tumors with rare survival beyond two years past diagnosis and limited understanding of the mechanism behind tumor invasion. Previous reports demonstrate upregulation protein ID1 H3K27M ACVR1 mutations in DMG, but this has not been confirmed human or therapeutically targeted.
SUMMARY An isoimmunohemolytic disease characterized by anemia and icterus of neonatal calves is reported. In some affected herds, 15 to 24% all newborn died from this disease. Most the became anemic jaundiced within 24 48 hours postpartum during first week life. Lesions observed in these included anemia, icterus, marked splenomegaly which was due massive sequestration erythrocytes. A few less severely survived acute episode returned normal health 2 3 weeks. Some birth a peracute form...
Sonic hedgehog (SHH) medulloblastoma is the most common molecular group of infant and early childhood (iMB) has no standard care at relapse. This work aimed to evaluate post-relapse survival (PRS) explore prognostic factors patients with nodular desmoplastic (ND) and/or SHH iMB. international retrospective study included 147 subjects diagnosed relapsed Nodular Desmoplastic/SHH iMB between 1995 2017, < 6 years old original diagnosis, treated without initial craniospinal irradiation (CSI)....
OBJECT Thirty-day mortality is increasingly a reference metric regarding surgical outcomes. Recent data estimate 30-day rate of 1.4-2.7% after craniotomy for tumors in children. No detailed analysis short-term following diagnostic neurosurgical procedure (e.g., resection or tissue biopsy) tumor the US pediatric population has been conducted. METHODS The Surveillance, Epidemiology and End Results (SEER) sets identified patients ≤ 21 years who underwent primary intracranial from 2004 to 2011....
Abstract Purpose: Genomic aberrations in cell cycle and PI3K pathways are commonly observed pediatric brain tumors. This study determined the MTD/recommended phase II dose (RP2D) of ribociclib everolimus characterized single-agent concentrations plasma tumor children undergoing resection. Patients Methods: were enrolled I according to a rolling 6 design received daily for 21 28 days, respectively. Surgical patients at RP2D (350 mg/m2) 7–10 days preoperatively followed by enrollment on study....
Abstract BACKGROUND RAS/RAF/MEK/ERK pathway activation is the primary driver for most pediatric low-grade gliomas (pLGG). MEK162 (binimetinib) an orally bioavailable MEK1/2 inhibitor with superior brain penetration in a preclinical model. The objective of this multi-institutional phase II and target validation study was to assess stratum-specific efficacy binimetinib progressive pLGG. METHODS Eligible children aged 1-18 years previously treated radiographically pLGG were enrolled...
Abstract Purpose: There are no effective treatment strategies for children with highest-risk posterior fossa group A ependymoma (PFA). Chromosome 1q gains (1q+) present in approximately 25% of newly diagnosed PFA tumors, and this number doubles at recurrence. Seventy percent chromosome 1q+ will die because the tumor, highlighting urgent need to develop new therapeutic population. Experimental Design: In study, we utilize vitro vivo models test efficacy combination radiation chemotherapy a...
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Central Nervous System Cancers provide multidisciplinary diagnostic workup, staging, and treatment recommendations diffuse high-grade gliomas medulloblastomas children adolescents. This article summarizes the studies panel discussion that serve as rationale comprehensive care included Cancers.
Abstract Children with ependymoma (EPN) are cured in less than 50% of cases, little improvement outcome over the last several decades. Chemotherapy has not affected survival EPN, due part to a lack preclinical models that precluded comprehensive drug testing. We recently developed two human EPN cell lines harboring high-risk phenotypes which provided us an opportunity execute translational studies. and other pediatric brain tumor were subject large-scale comparative screen FDA-approved...
Ependymoma (EPN) is a common brain tumor of childhood that, despite standard surgery and radiation therapy, has relapse rate 50%. Clinical trials have been unsuccessful in improving outcome by addition chemotherapy, identification novel therapeutics hampered lack vitro vivo models. We describe 2 unique EPN cell lines (811 928) derived from recurrent intracranial metastases. Both harbor the high-risk chromosome 1q gain (1q+) derivative 6, both are classified as molecular group A according to...
Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can adolescents and adults. The purpose of this study was to describe clinical, radiological, pathologic, molecular characteristics patients ≥10 years age with DIPG enrolled the International Registry (IDIPGR).Patients at diagnosis IDIPGR imaging confirmed were included. primary outcome overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term (STS) (<24...
Hundreds of systemic chemotherapy trials in diffuse intrinsic pontine glioma (DIPG) have not improved survival, potentially due to lack intratumoral penetration, which has previously been assessed humans.We used gemcitabine as a model agent assess DIPG pharmacokinetics (PK) using mass spectrometry.In phase 0 clinical trial i.v. prior biopsy children newly diagnosed with by MRI, mean concentration 4 cores patient 1 (H3K27M midline glioma) was 7.65 µM. These compare favorably levels for 2...
Ras/Raf/MEK/ERK pathway activation is the primary driver of most pediatric low-grade gliomas (LGG). MEK162 an orally bioavailable MEK1/2 inhibitor. The objective this first-in-children multi-institutional open-label dose-escalation trial was to determine maximum tolerated dose (MTD) oral suspension in children. Children aged 1-18 years with recurrent, refractory or progressive LGG and other non-hematologic malignancies associated Ras/Raf were enrolled according a 3 + design. Partial response...